<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id>
      <journal-id journal-id-type="publisher-id">jbc</journal-id>
      <journal-title>The Journal of Biological Chemistry</journal-title>
      <issn pub-type="ppub">0021-9258</issn>
      <issn pub-type="epub">1083-351X</issn>
      <publisher>
        <publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18227068</article-id>
      <article-id pub-id-type="pmc">2447622</article-id>
      <article-id pub-id-type="publisher-id">10930</article-id>
      <article-id pub-id-type="doi">10.1074/jbc.M707451200</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Protein Synthesis, Post-Translational Modification, and  Degradation</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Decreasing Intracellular Superoxide Corrects Defective Ischemia-induced
 New Vessel Formation in Diabetic
 Mice<xref ref-type="fn" rid="fn1">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ceradini</surname>
            <given-names>Daniel J.</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1d00ec0N0x1eac330">&#x2021;</xref>
          <xref ref-type="fn" rid="fn2">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yao</surname>
            <given-names>Dachun</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1d00ec0N0x1eac330">&#xA7;</xref>
          <xref ref-type="fn" rid="fn2">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grogan</surname>
            <given-names>Raymon H.</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1d00ec0N0x1eac330">&#x2021;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Callaghan</surname>
            <given-names>Matthew J.</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1d00ec0N0x1eac330">&#x2021;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Edelstein</surname>
            <given-names>Diane</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1d00ec0N0x1eac330">&#xA7;</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brownlee</surname>
            <given-names>Michael</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1d00ec0N0x1eac330">&#xA7;</xref>
          <xref ref-type="corresp" rid="cor1">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gurtner</surname>
            <given-names>Geoffrey C.</given-names>
          </name>
          <xref ref-type="aff" rid="N0x1d00ec0N0x1eac330">&#x2021;</xref>
        </contrib>
      </contrib-group>
      <aff id="N0x1d00ec0N0x1eac330"><label>&#x2021;</label>Department of Surgery,
 Stanford University School of Medicine, Stanford, California 94305-5148 and
 the <label>&#xA7;</label>JDRF International Center for
 Diabetic Complications Research, Albert Einstein College of Medicine, Bronx,
 New York 10461-1602</aff>
      <author-notes>
        <fn id="fn2">
          <label>1</label>
          <p>Both authors contributed equally to the work.</p>
        </fn>
        <fn id="cor1">
          <label>2</label>
          <p>
 To whom correspondence should be addressed: F-531, 1300 Morris Park Ave.,
 Bronx NY 10461. Tel.: 718-430-3636; Fax: 718-430-8570; E-mail:
 <email>brownlee@aecom.yu.edu</email>.
 </p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>18</day>
        <month>4</month>
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>18</day>
        <month>4</month>
        <year>2009</year>
      </pub-date>
      <!-- PMC Release delay is 12 months and 0 days and was based on the copyright element. -->
      <volume>283</volume>
      <issue>16</issue>
      <fpage>10930</fpage>
      <lpage>10938</lpage>
      <history>
        <date date-type="received">
          <day>5</day>
          <month>9</month>
          <year>2007</year>
        </date>
        <date date-type="rev-recd">
          <day>7</day>
          <month>1</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2008, The American Society for Biochemistry and
 Molecular Biology, Inc.</copyright-statement>
      </permissions>
      <self-uri xlink:title="pdf" xlink:href="zbc01608010930.pdf"/>
      <abstract>
        <p>Tissue ischemia promotes vasculogenesis through chemokine-induced
 recruitment of bone marrow-derived endothelial progenitor cells (EPCs).
 Diabetes significantly impairs this process. Because hyperglycemia increases
 reactive oxygen species in a number of cell types, and because many of the
 defects responsible for impaired vasculogenesis involve HIF1-regulated genes,
 we hypothesized that HIF1 function is impaired in diabetes because of reactive
 oxygen species-induced modification of HIF1&#x3B1; by the glyoxalase 1 (GLO1)
 substrate methylglyoxal. Decreasing superoxide in diabetic mice by either
 transgenic expression of manganese superoxide dismutase or by administration
 of an superoxide dismutase mimetic corrected post-ischemic defects in
 neovascularization, oxygen delivery, and chemokine expression, and normalized
 tissue survival. In hypoxic fibroblasts cultured in high glucose,
 overexpression of GLO1 prevented reduced expression of both the EPC mobilizing
 chemokine stromal cell-derived factor-1 (SDF-1) and of vascular epidermal
 growth factor, which modulates growth and differentiation of recruited EPCs.
 In hypoxic EPCs cultured in high glucose, overexpression of GLO1 prevented
 reduced expression of both the SDF-1 receptor CXCR4, and endothelial
 nitric-oxide synthase, an enzyme essential for EPC mobilization. HIF1&#x3B1;
 modification by methylglyoxal reduced heterodimer formation and HIF1&#x3B1;
 binding to all relevant promoters. These results provide a basis for the
 rational design of new therapeutics to normalize impaired ischemia-induced
 vasculogenesis in patients with diabetes.</p>
      </abstract>
    </article-meta>
    <notes>
      <fn-group>
        <fn id="fn1">
          <label>*</label>
          <p>This work was supported by <grant-sponsor>NIDDK</grant-sponsor>,
 <grant-sponsor>National Institutes of
 Health</grant-sponsor> Grants <grant-num>R01
 DK74153-01</grant-num> (to M. B.) and <grant-num>R01 DK74095-01</grant-num>
 (to G. G.). The costs of publication of this article were defrayed in part by
 the payment of page charges. This article must therefore be hereby marked
 &#x201C;<italic>advertisement</italic>&#x201D; in accordance with 18 U.S.C. Section 1734
 solely to indicate this fact.</p>
        </fn>
      </fn-group>
    </notes>
  </front>
</article>
</pmc-articleset>